Biocodex laboratories join Future4care!

Paris, April 13. Biocodex, a pioneer and major international player in the field of microbiota and women's health, has joined Future4care as a new member.
The arrival of this company, with more than 1,600 employees, reinforces the multidisciplinary approach sought by the founders of Future4care.

Published on 11 April 2022 at 10h08

Biocodex has been investing for several years in startups focused on microbiota, its main area of expertise. The partnership with Future4care will enable Biocodex to accelerate its development in digital health and to take its place in this ecosystem of excellence.

Future4care and Biocodex share the same convictions, first and foremost that of bringing together the players in the ecosystem to make possible the innovations that will make tomorrow's healthcare possible, for the benefit of the patient. By joining the initiative, Biocodex will contribute to the "manufacturing" of solutions that address the issues of sovereignty on a European scale for health data and the question of how to manage their use.

Nicolas Coudurier, CEO of Biocodex, said: "We are very honored to be the first pharmaceutical industry partner chosen by the founders of Future4Care. Biocodex will contribute to the tremendous momentum created by this consortium in the service of tomorrow's health. Our industry must create links with players in the healthcare, digital and start-up sectors to address our new challenges, including societal ones, such as prevention, beyond data. Biocodex is committed to its patients; Biocodex is also committed to its employees who will benefit from the scheme proposed by Future4Care, which illustrates the acceleration in our transformation."

As a member of the Future4care Selection Committee, Biocodex will thus play a fundamental role within the ecosystem, in terms of governance, to:

  • Define the annual themes and illustrations of Future4care ;
  • Take part in the choice of selection criteria for the selected startups;
  • Participate in setting the guidelines for the work of the Future4Care Institute ;
  • Contribute to the entry of new members.

  Biocodex will also participate in the selection of startups during the various calls for projects launched every six months. The new member will also benefit from access to the Future4care open innovation platform and a set of acculturation, collaboration and influence services. They will also be asked to contribute to the work of the Future4care Institute.  For more information, please visit

About Future4care

Future4care is the European accelerator for e-health startups, born from the alliance between Capgemini, Generali, Orange and Sanofi. Its objective is to accelerate the market launch of solutions capable of becoming European e-health champions. An ecosystem on a scale that is unique in Europe, Future4care consists of:  

  • A 6400m2 space in the heart of Paris in the 13th arrondissement in the Biopark to best support startups in their acceleration phase;
  • An open innovation platform to facilitate acculturation, collaboration and influence within the community
  • An Institute, a true knowledge center that will offer programs and conferences related to digital health ;
  • A reference label. 

About Biocodex

Biocodex is a French pharmaceutical company founded in 1953 around the development and marketing of the world's first probiotic yeast strain, Saccharomyces boulardii CNCM I-745. Today, Biocodex is developing around three pillars: microbiota, women's health and orphan diseases. Biocodex employs more than 1,600 people and had net sales of €418 million in 2021, of which 42% in France and 58% internationally. The Biocodex Group is present in 124 countries, including 20 countries through its own subsidiaries. Its products are distributed in the rest of the world by partner companies.


FInd, here, the interview of Nicolas Coudurier, CEO of Biocodex.